Delcath Q1 FY26 net income turns to $1.1 million loss; revenue rises 26% to $25 million

• Delcath Systems posted Q1 2026 revenue of $25 million, up 26.26% year over year.
• Net results swung to a loss of $1.1 million from net income a year earlier; gross margin slipped 1 percentage point to 85%.
• HEPZATO KIT revenue rose to $23.3 million, supported by about 36% growth in HEPZATO volume year over year.
• R&D expense climbed to $9.8 million on higher costs tied to expanding the clinical team and continuing Phase 2 trials; SG&A increased to $13.1 million on commercial expansion activities.
• Full-year 2026 outlook calls for total CHEMOSAT and HEPZATO KIT revenue of at least $100 million, gross margin of 84% to 87%, and positive adjusted EBITDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260507125922) on May 07, 2026, and is solely responsible for the information contained therein.